Free tool
FAERS Monitor: Cardizem Cd
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020062 or its brand name (Cardizem Cd, Diltiazem Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
14,723
Serious
12,051
82% of reports
Hospitalization
6,837
Death reported
3,123
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea1,626
- pain1,418
- fatigue1,372
- fall1,184
- nausea1,095
- dizziness1,075
- headache1,075
- diarrhoea1,056
- drug ineffective1,039
- arthralgia1,021
- hypotension952
- pruritus931
- off label use905
- pyrexia897
- hypersensitivity847
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 500 |
| 2005 | 507 |
| 2006 | 366 |
| 2007 | 256 |
| 2008 | 263 |
| 2009 | 261 |
| 2010 | 346 |
| 2011 | 334 |
| 2012 | 459 |
| 2013 | 426 |
| 2014 | 504 |
| 2015 | 445 |
| 2016 | 572 |
| 2017 | 521 |
| 2018 | 473 |
| 2019 | 502 |
| 2020 | 675 |
| 2021 | 990 |
| 2022 | 1,520 |
| 2023 | 1,163 |
| 2024 | 1,429 |
| 2025 | 1,387 |
| 2026 | 824 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,436 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypotensionSignal | 952 | 6.8 | 6.4 | 4,734 |
| hypersensitivitySignal | 847 | 6.5 | 6.1 | 3,990 |
| fallSignal | 1,184 | 5.1 | 4.8 | 3,943 |
| dyspnoeaSignal | 1,626 | 4.1 | 3.9 | 3,921 |
| pyrexiaSignal | 897 | 3.7 | 3.5 | 1,798 |
| arthralgiaSignal | 1,021 | 3.5 | 3.3 | 1,866 |
| pruritusSignal | 931 | 3.5 | 3.3 | 1,658 |
| painSignal | 1,418 | 3.3 | 3.1 | 2,338 |
| dizzinessSignal | 1,075 | 3.1 | 2.9 | 1,545 |
| fatigueSignal | 1,372 | 2.5 | 2.4 | 1,303 |
| headacheSignal | 1,075 | 2.5 | 2.3 | 950 |
| diarrhoeaSignal | 1,056 | 2.3 | 2.2 | 833 |
| nausea | 1,095 | 2.0 | 1.9 | 548 |
| off label use | 905 | 1.5 | 1.4 | 145 |
| drug ineffective | 1,039 | 1.1 | 1.1 | 16 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.